Valuation: Nanobiotix

Market Cap 1.64B 1.9B 1.54B 1.4B 2.63B 181B 2.68B 18.04B 7.05B 90.82B 7.12B 6.97B 302B P/E 2026 *
-78.6x
P/E 2027 * -136x
Enterprise Value 1.68B 1.95B 1.58B 1.44B 2.71B 186B 2.75B 18.54B 7.25B 93.37B 7.32B 7.16B 310B EV / Sales 2026 *
44.2x
EV / Sales 2027 * 40x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-2.65%
1 week-3.47%
Current month-4.21%
1 month-3.52%
3 months-26.29%
6 months+51.64%
Current year+65.64%
1 week 32.02
Extreme 32.02
35.24
1 month 31.04
Extreme 31.04
36.04
Current year 16.66
Extreme 16.66
47.66
1 year 6.92
Extreme 6.92
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%-3.47%+368.12%+305.78% 1.9B
-1.78%-1.68%+1.48%+17.26% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
+0.49%+0.92%+4.11%+26.37% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -0.86%-0.38%+110.25%+138.28% 26.5B
Weighted average by Cap. -0.93%-0.14%+97.90%+141.52%

Financials

2026 *2027 *
Net sales 38.06M 44.07M 35.77M 32.53M 61.15M 4.21B 62.16M 419M 164M 2.11B 165M 162M 7.01B 42.83M 49.58M 40.24M 36.6M 68.81M 4.74B 69.94M 472M 184M 2.37B 186M 182M 7.89B
Net income -12.18M -14.1M -11.44M -10.41M -19.56M -1.35B -19.89M -134M -52.42M -675M -52.93M -51.78M -2.24B -52.44K -60.72K -49.28K -44.82K -84.26K -5.81M -85.65K -577K -226K -2.91M -228K -223K -9.66M
Net Debt 46M 53.26M 43.23M 39.31M 73.91M 5.09B 75.13M 506M 198M 2.55B 200M 196M 8.47B 76.4M 88.46M 71.8M 65.29M 123M 8.46B 125M 841M 329M 4.24B 332M 325M 14.08B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-08-14 €32.30 -2.65% 116,123
26-08-13 €33.18 -3.88% 194,727
26-08-12 €34.52 +3.42% 65,801
26-08-11 €33.38 +2.71% 192,490
26-08-10 €32.50 -2.87% 105,429
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
32.30EUR
Average target price
52.20EUR
Spread / Average Target
+61.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock